Announcements Trials
Browse Landscape

Status

Recruiting 2Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Conditions

Breast Neoplasms 1387Neoplasms 1164Colorectal Neoplasms 624Lung Neoplasms 559Prostatic Neoplasms 538Carcinoma, Non-Small-Cell Lung 443Carcinoma, Hepatocellular 296Stomach Neoplasms 272Pancreatic Neoplasms 270Colonic Neoplasms 264Ovarian Neoplasms 230Head and Neck Neoplasms 228Rectal Neoplasms 221Melanoma 215Multiple Myeloma 202Uterine Cervical Neoplasms 198Lymphoma 195Leukemia 193Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Neoplasm Metastasis 178Carcinoma, Renal Cell 177Esophageal Neoplasms 173Brain Neoplasms 173Leukemia, Myeloid, Acute 158Urinary Bladder Neoplasms 138Recurrence 123Polycystic Ovary Syndrome 122Liver Neoplasms 118Hematologic Neoplasms 117Endometrial Neoplasms 107

Interventions

Selective Serotonin Reuptake Inhibitors 1Antidepressive Agents, Tricyclic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Observational × Depressive Disorder × Clear all
NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

Completed
50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡